Constipation Treatment Market Report 2025

The constipation treatment market size has grown strongly in recent years. It will grow from $11.72 billion in 2024 to $12.39 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to the rising prevalence of digestive disorders, demographic changes, lifestyle factors, limited treatment options, and increasing awareness of health issues.

The constipation treatment market size is expected to see strong growth in the next few years. It will grow to $16.62 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to rising healthcare expenditure, increased focus on preventive healthcare, focus on pediatric constipation, growing demand for personalized healthcare solutions, the rise of telemedicine, expansion of e-commerce, focus on functional foods and probiotics. Major trends in the forecast period include technological advancements in healthcare, artificial intelligence and machine learning in healthcare, focus on sustainability and eco-friendly products, collaboration between healthcare providers and technology companies, and increased investment in R&D by pharmaceutical companies.

The upward trend in the consumption of fast food is anticipated to drive the growth of the constipation treatment market. Fast food, characterized by its quick preparation and service, often lacks sufficient fiber and tends to be high in fat and salt, contributing to constipation-related issues. As reported in August 2023 by Budget Branders, a US-based provider of paper and plastic products, the global market value of the fast food industry is projected to reach $931.7 billion by 2027. The US alone boasts over 200,000 distinct fast-food outlets, with consumers annually spending a staggering $200 billion on fast food. This surge in fast-food consumption underlines the growing need for constipation treatment solutions.

The increasing incidence of gastrointestinal disorders is expected to drive the growth of the constipation treatment market in the future. Gastrointestinal disorders, commonly known as digestive disorders, include a range of conditions affecting the digestive tract. Constipation is a frequent symptom associated with many gastrointestinal (GI) disorders. The rising prevalence of gastrointestinal disorders, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), is propelling the growth of the constipation treatment market, as these conditions often occur alongside constipation, creating a greater demand for specific and effective treatments amid heightened awareness. For instance, in January 2024, the American Cancer Society, a US-based non-profit organization, projected approximately 26,890 new cases of stomach cancer in the U.S. for 2024, with 16,160 cases in men and 10,730 in women. This type of cancer is also expected to result in around 10,880 deaths, including 6,490 men and 4,390 women. Therefore, the rising incidence of gastrointestinal disorders is driving the growth of the constipation treatment market.

Product innovation emerges as a pivotal trend gaining traction in the constipation treatment market. Companies operating in this market are strategically focusing on developing novel products to fortify their market position. A notable example is Ardelyx, a US-based biopharmaceutical company, which introduced IBSRELA in April 2022. IBSRELA represents a breakthrough treatment for irritable bowel syndrome with constipation (IBS-C) in adults, being the first-in-class therapy developed in over a decade. This innovative medication addresses symptoms such as constipation, bloating, and stomach pain, offering a substantial new treatment option for individuals affected by IBS-C.

Major players in the constipation treatment market are actively engaged in the development of groundbreaking products, including ready-to-drink suspensions, aiming to cater to a broader customer base, drive increased sales, and boost overall revenue. For instance, in October 2022, Navamedic ASA, a Norway-based pharmaceutical company, unveiled ForlaxGo. This unique product serves as a convenient solution for occasional constipation, providing on-the-go ease with its ready-to-drink suspension format. Tailored for adults and children over 8 years old, ForlaxGO features macrogol as its primary component, delivering a natural sense of relief. Its standout characteristic lies in the presentation as a pre-measured, single-dose sachet, offering a hassle-free, ready-to-use solution. Significantly, ForlaxGO is available over-the-counter at pharmacies, eliminating the need for a prescription. This strategic approach to product innovation underscores the commitment of major companies to meet evolving consumer needs in the constipation treatment market.

In March 2023, Ipsen, a pharmaceutical company headquartered in France, completed the acquisition of Albireo Pharma Inc. The specific financial details of this acquisition were not disclosed. Ipsen's strategic acquisition of Albireo Pharma Inc. signifies a move to enhance its portfolio within the realm of rare diseases. Albireo Pharma Inc., based in the United States, specializes in biotechnology and focuses on the development of medications targeting chronic constipation treatment. This acquisition is expected to strengthen Ipsen's presence and offerings in the field of rare disease therapeutics, particularly in addressing chronic constipation-related treatments and solutions.

Major companies operating in the constipation treatment market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Fresenius Kabi AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Bausch Health Companies Inc., Eisai Co. Ltd., Shionogi & Co. Ltd., Mallinckrodt Plc, Salix Pharmaceuticals Inc., Prestige Consumer Healthcare Inc., Taiho Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals NV, Ferring Pharmaceuticals, RedHill Biopharma Ltd., Probi AB, 4D Pharma plc.

North America was the largest region in the constipation treatment market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the constipation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Constipation treatment encompasses various methods and strategies aimed at alleviating and managing the condition, characterized by irregular or challenging bowel movements, often resulting in hard or dry stools. These treatments aim to address symptoms and promote regularity in bowel function.

The primary therapeutic approaches for treating constipation include various categories such as laxatives, chloride channel activators, peripherally acting mu-opioid receptor antagonists, GC-C (guanylate cyclase-c) agonists, and other related remedies. Laxatives, for instance, facilitate the passage of stool in the intestines, aiding in constipation treatment by enhancing stool size, frequency, and motility. They are commonly utilized in managing chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC). These treatments are made available through multiple distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacy platforms.

The constipation treatment market research report is one of a series of new reports that provides constipation treatment market statistics, including constipation treatment industry global market size, regional shares, competitors with a constipation treatment market share, detailed constipation treatment market segments, market trends and opportunities, and any further data you may need to thrive in the constipation treatment industry. This constipation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The constipation treatment market consists of sales of polyethylene glycol, bisacodyl, tegaserod, lubiprostone, and senna. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.